[ribosometronome]

It seems like all of their criticisms can be easily applied to essentially any technology used or medical company relied on.

For example: >In the rush to deploy off-the-shelf proprietary LLMs, however, health-care institutions and other organizations risk ceding the control of medicine to opaque corporate interests. Medical care could rapidly become dependent on LLMs that are difficult to evaluate, and that can be modified or even taken offline without notice should the service be deemed no longer profitable

Even:

>LLMs often generate ... convincing outputs that are false

is already a problem the medical community has to address with existing tests.

Or:

>Another problem specific to proprietary LLMs is that companies’ dependency on profits creates an inherent conflict of interest that could inject instability into the provision of medical care.

Seemingly applies to essentially the entirety of medical supplies and medications.